Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Shares Issued (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Shares Issued for 12 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued rose 242.25% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.7 million, a 94.6% decrease, with the full-year FY2024 number at $773000.0, down 69.08% from a year prior.
  • Shares Issued was $1.3 million for Q3 2025 at Gyre Therapeutics, down from $1.5 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $49.3 million in Q1 2021 to a low of -$534000.0 in Q4 2024.
  • A 3-year average of $6.7 million and a median of $583500.0 in 2024 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 437.82% in 2025; the steepest drop was 22.64% in 2025.
  • Gyre Therapeutics' Shares Issued stood at $49.3 million in 2021, then crashed by 101.08% to -$534000.0 in 2024, then surged by 339.7% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Shares Issued are $1.3 million (Q3 2025), $1.5 million (Q2 2025), and $509000.0 (Q1 2025).